<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83646">
  <stage>Registered</stage>
  <submitdate>25/02/2009</submitdate>
  <approvaldate>30/09/2011</approvaldate>
  <actrnumber>ACTRN12611001036909</actrnumber>
  <trial_identification>
    <studytitle>Prevention and immunisation of cervical cancer amongst school girls in Vanuatu</studytitle>
    <scientifictitle>A sustainable program for prevention of Cervical Cancer in school girls in Vanuatu</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cervical cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A series of 1 hour long focus groups will be conducted in 10 participating villages, by the district nurses in English and Bislami to ascertain the beliefs of vaccination and cervical cancer immunisation program amongst government officials, parents and 10-12 year old school girls . The findings from the sessions will be used to lay the vaccination program in Vanuatu. Hence these sessions happen prior to the 3 shots of vaccine. 
1000 school girls will be educated about cervical cancer and immunised intravenously with 3 doses of Cervarix (0.5 ml per dose) by a dedicated nurse across 10 villages. HPV antibody levels will be measured 3 months after the final dose of the vaccine delivered to a 0,2.5,6 month schedule. The collected sera will then be tested in a WHO lab.</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Uptake of HPV vaccination: percentage of 10-12 year old girls recruited in the study.</outcome>
      <timepoint>one year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Personal card record systems. This is to verify that the participants return back for the 3 shots of vaccine within the nominated time period.</outcome>
      <timepoint>one year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship of age and nutrition with the immune responses to HPV infection. Sera collected pre and post immunisation, together with the participant personal information such as weight and height will be used to assess this information.</outcome>
      <timepoint>one year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HPV antibody test for the vaccine using ELISA assay. The assay demonstrates the presence of type specific IgG antibody present in the sera post immunisation. All participants immunised with Cervarix should demonstrate the presence of HPV 16 and HPV 18 antibodies.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age 9 - 12 years old school girls</inclusivecriteria>
    <inclusiveminage>9</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. younger than 9 and older than 12 women
2. who currently receive any immunology modifier meditation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>21/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Vanuatu</country>
      <state>Port Vila</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Queensland</primarysponsorname>
    <primarysponsoraddress>St Lucia, Brisbane 
QLD - 4067</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>GlaxoSmithKline Biologicals</fundingname>
      <fundingaddress>1061 Mountain Hwy  (PO Box 168) 
Boronia VIC 3155</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Ian Frazer</sponsorname>
      <sponsoraddress>Translational Research Institute Pty Ltd.
20 Cornwall Street
Wooloongabba
QLD - 4102</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Margaret McAdam</othercollaboratorname>
      <othercollaboratoraddress>Wesley Hospital
451, Coronation drive
Auchenflower
QLD - 4066</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Engagement of the Ni-Vanuatu women will enable effective delivery of Cervarix vaccine to a cohort of 10-12 year old school girls. Efficient monitoring and follow up will lead to the prevention of cervical cancer in Vanuatu.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Queensland Human Ethics Committee</ethicname>
      <ethicaddress>The University of Queensland
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072</ethicaddress>
      <ethicapprovaldate>14/01/2009</ethicapprovaldate>
      <hrec>2008002173</hrec>
      <ethicsubmitdate>26/11/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Ian Frazer</name>
      <address>Translational Research Institute Pty Ltd.
20 Cornwall Street,
Wooloongabba
QLD - 4102</address>
      <phone>+61 7 3346 1905</phone>
      <fax>+61 7 3346 1732</fax>
      <email>ian.frazer@tri.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Margaret McAdam</name>
      <address>Wesley Hospital,
451, Coronation Drive
Auchenflower
QLD - 4066.</address>
      <phone>+61 419622326</phone>
      <fax />
      <email>mcadamia@bigpond.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Rohit Sinha</name>
      <address>University of Queensland Diamantina Institute
R-Wing, Building 1
Princess Alexandra Hospital
Ipswich Road, Buranda QLD 4102, Brisbane</address>
      <phone>+61 7 3176 5942</phone>
      <fax>+61 7 3176 5349</fax>
      <email>r.sinha@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>